Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Beyond Meat, McDermott International, and Pfizer Slumped Today

By Dan Caplinger - Jul 30, 2019 at 4:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sometimes even solid growth isn't enough to lift a stock's price.

Tuesday was a down day on Wall Street, but losses were relatively muted as investors tried to position themselves for some big news coming in the near future. The Federal Reserve began its two-day meeting on monetary policy, and most market participants expect the central bank to cut short-term interest rates on Wednesday. Yet not everyone thinks that'll be enough to keep the economy growing, especially if companies disappoint with their earnings results. Beyond Meat ( BYND 4.04% ), McDermott International ( MDR ), and Pfizer ( PFE -0.62% ) were among the worst performers. Here's why they did so poorly.

Beyond Meat wilts

Shares of Beyond Meat dropped 12% following the plant-based protein maker's second-quarter earnings report. Fundamentally, the company seemed strong, as revenue nearly quadrupled from year-ago levels. Yet even though adjusted pre-tax operating earnings reversed a prior-year loss with a modest gain, Beyond Meat also announced a secondary stock offering, with current shareholders selling 3 million shares and the company adding another 250,000 shares to the mix. The big share-price decline still leaves Beyond Meat with an impressive gain since its IPO, with the stock staying at triple its opening day price.

Beyond Meat logo with slogan in black and red.

Image source: Beyond Meat.

McDermott runs out of gas

McDermott International's stock plummeted 35% after the engineering company released its second-quarter financial results. McDermott lost money unexpectedly, and it struggled to consolidate its acquisition of Chicago Bridge & Iron. On a positive note, backlog and new order figures were encouraging, and CEO David Dickson said that the order activity points to sustained growth for 2020. However, McDermott cut its guidance for 2019 due to weak operating results, scheduling issues, and a shift in some expected incentive awards. In order to recover fully, McDermott will need to see an even healthier energy industry drive up demand for its construction services in the sector.

Pfizer gets criticized

Finally, shares of Pfizer closed lower by 6.5%. The drugmaker made a big move on Monday when it announced plans to merge its Upjohn generic and off-patent drug portfolio with Mylan, but investors weren't entirely comfortable with the strategic decision. Today, stock analysts at Morgan Stanley weighed in, and they agreed that the move could be problematic. Morgan Stanley cut its rating on Pfizer from overweight to equal weight and slashed its price target by $8 per share to $40. With Upjohn expected to get separated from the rest of Pfizer through a spinoff, the remainder of the pharmaceutical giant's operations might not do as well as some think. Shareholders appear to believe that's a problematic factor for Pfizer going forward.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.40 (-0.62%) $0.32
McDermott International, Inc. Stock Quote
McDermott International, Inc.
MDR
Beyond Meat Stock Quote
Beyond Meat
BYND
$74.13 (4.04%) $2.88

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
652%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.